Ociperlimab | m-entrepreneurship.com

Product Name :
Ociperlimab

Search keywords :
Ociperlimab

drugId :
null

Target Vo:
T cell immunoglobulin and ITIM domains

Target Vo Short Name :
TIGIT

Moa_Name:
T cell immunoglobulin and ITIM domains inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Beigene Ltd

Active Company_Name :
Beigene Guangzhou Biologics Manufacturing Co Ltd

Active Indication_Name:
Carcinoma, Non-Small-Cell Lung

In Active Indication_Name:
Cholangiocarcinoma

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
NFAT2 Antibody
B-Raf Antibody
SP7/Osterix Antibody: SP7/Osterix Antibody is an unconjugated, approximately 45 kDa, rabbit-derived, anti-SP7/Osterix polyclonal antibody. SP7/Osterix Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat, dog, pig, cow, horse, rabbit background without labeling.

Author: Betaine hydrochloride

Related Posts